DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Glyburide (RP-1127) for Traumatic Brain Injury (TBI)

Information source: Remedy Pharmaceuticals, Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Traumatic Brain Injury

Intervention: Glyburide (Drug); Placebo (Drug)

Phase: Phase 2

Status: Active, not recruiting

Sponsored by: Remedy Pharmaceuticals, Inc.

Official(s) and/or principal investigator(s):
Howard Eisenberg, MD, Principal Investigator, Affiliation: University of Maryland


This is a randomized, double-blind, placebo-controlled, multi-institutional study of IV RP-1127 (Glyburide for Injection) begun within 10 hours of complicated mild, moderate or severe traumatic brain injury (TBI).

Clinical Details

Official title: A Randomized Clinical Trial of Glyburide (RP-1127) for TBI

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome:

Change in Edema from Baseline

Change in Hemorrhage from Baseline

Safety i.e. the incidence of mortality, adverse events, and serious adverse events

Detailed description: The primary efficacy objective of this study is to assess whether patients with severe, moderate, or complicated mild TBI administered RP-1127 will show a decrease in MRI-defined edema and/or hemorrhage, compared to patients administered placebo. The primary safety objective is to assess the safety and tolerability of RP-1127 compared to placebo in patients with severe, moderate, or complicated mild TBI.


Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Both.


Inclusion Criteria: 1. Documented closed head TBI 2. Clearly defined time of injury no more than 10 hours before administration of study drug/placebo 3. GCS 4-14. The GCS will be obtained free of the effects of sedating and/or paralytic drug. Complicated mild must have GCS 13-14 and one or more of the following: Intraparenchymal clots or contusions in aggregate > 10cc; Midline shift > 5mm; IVH, SDH, EDH seen on more than one CT scan slice. 4. Age 18-75 years 5. Patients in whom a dedicated peripheral IV line can be placed for study drug administration 6. Written consent obtained from legally authorized representative (LAR) Exclusion Criteria: 1. No documented TBI or time of impact not certain 2. Penetrating brain injury 3. Spinal column instability and/or spinal cord injury with neurodeficit 4. Concomitant severe non survivable injury 5. Pregnant, or a positive pregnancy test 6. Women who intend to breastfeed during Study Days 1-4. 7. Blood glucose <50mg/dL 8. Severe renal disorder from the patient's history (e. g. dialysis) or serum creatinine of > 2. 5 mg/dL 9. Severe liver disease or total bilirubin >1. 5 times upper limit of normal 10. INR>1. 4 11. Systolic BP<90 mm Hg not responsive to fluid resuscitation 12. Blood alcohol > 250mg/dL 13. Inability to have MRI (pacemaker, non-MR compatible pressure monitor, etc.) 14. Hospitalization for brain injury, psychiatric or neurological disease within previous 3 years 15. Emergent or urgent surgical operation anticipated (in OR, bedside procedures excluded) that would prevent dosing with study drug within 8 hours of injury. 16. Known use of Coumadin (warfarin), Plavix (clopidogrel), Effient (prasugrel) or Pletal (cilostazol), heparin, low molecular weight heparin, heparinoids, or abciximab or similar antiplatelet agents in the previous 72 hours (Note that patients later found to have taken these medications will not be automatically excluded from the study.) 17. Use of sulfonylurea drugs within the prior 30 days 18. Treatment with another investigational drug within the prior 30 days 19. Allergy to sulfonylurea drugs 20. Known diagnosis of G6PD enzyme deficiency 21. PaO2 < 60 mm Hg on admission (for patients in whom blood gases are drawn per standard of care) 22. Non-English speaking legally authorized representative and subjects (University of Maryland only) 23. Prisoners or others who may be unable to make a truly voluntary and uncoerced decision whether or not to participate in the study 24. Any other clinical condition which in the opinion of the investigator makes the patient unsuitable for inclusion into the study

Locations and Contacts

University of California, San Diego, San Diego, California 92103, United States

University of Maryland Medical Center, Shock Trauma Center, Baltimore, Maryland 21201, United States

UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania 15213, United States

VCU Medical Center, Richmond, Virginia 23298, United States

Additional Information

Starting date: November 2011
Last updated: May 5, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017